137 related articles for article (PubMed ID: 22030027)
1. Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.
Kim J; Hong S; Hong S
Bioorg Med Chem Lett; 2011 Dec; 21(23):6977-81. PubMed ID: 22030027
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 4-morpholino-pyrimidin-6-one and 4-morpholino-pyrimidin-2-one-containing Phosphoinositide 3-kinase (PI3K) p110β isoform inhibitors through structure-based fragment optimisation.
Giordanetto F; Wållberg A; Cassel J; Ghosal S; Kossenjans M; Yuan ZQ; Wang X; Liang L
Bioorg Med Chem Lett; 2012 Nov; 22(21):6665-70. PubMed ID: 23010274
[TBL] [Abstract][Full Text] [Related]
3. Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.
Heffron TP; Wei B; Olivero A; Staben ST; Tsui V; Do S; Dotson J; Folkes AJ; Goldsmith P; Goldsmith R; Gunzner J; Lesnick J; Lewis C; Mathieu S; Nonomiya J; Shuttleworth S; Sutherlin DP; Wan NC; Wang S; Wiesmann C; Zhu BY
J Med Chem; 2011 Nov; 54(22):7815-33. PubMed ID: 21985639
[TBL] [Abstract][Full Text] [Related]
4. Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase β isoform.
Staben ST; Ndubaku C; Blaquiere N; Belvin M; Bull RJ; Dudley D; Edgar K; Gray D; Heald R; Heffron TP; Jones GE; Jones M; Kolesnikov A; Lee L; Lesnick J; Lewis C; Murray J; McLean NJ; Nonomiya J; Olivero AG; Ord R; Pang J; Price S; Prior WW; Rouge L; Salphati L; Sampath D; Wallin J; Wang L; Wei B; Weismann C; Wu P
Bioorg Med Chem Lett; 2013 May; 23(9):2606-13. PubMed ID: 23540645
[TBL] [Abstract][Full Text] [Related]
5. Discovery and optimization of new benzimidazole- and benzoxazole-pyrimidone selective PI3Kβ inhibitors for the treatment of phosphatase and TENsin homologue (PTEN)-deficient cancers.
Certal V; Halley F; Virone-Oddos A; Delorme C; Karlsson A; Rak A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Carry JC; Abecassis PY; Lejeune P; Vincent L; Bonnevaux H; Nicolas JP; Bertrand T; Marquette JP; Michot N; Benard T; Below P; Vade I; Chatreaux F; Lebourg G; Pilorge F; Angouillant-Boniface O; Louboutin A; Lengauer C; Schio L
J Med Chem; 2012 May; 55(10):4788-805. PubMed ID: 22524426
[TBL] [Abstract][Full Text] [Related]
6. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.
Zhu J; Pan P; Li Y; Wang M; Li D; Cao B; Mao X; Hou T
Mol Biosyst; 2014 Mar; 10(3):454-66. PubMed ID: 24336903
[TBL] [Abstract][Full Text] [Related]
7. Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
Park H; Choi H; Hong S; Kim D; Oh DS; Hong S
Bioorg Med Chem Lett; 2011 Apr; 21(7):2021-4. PubMed ID: 21354792
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of PI3Kβ-selective inhibition revealed by reciprocal mutagenesis.
Zheng Z; Miller MS; Jennings IG; Thompson PE
ACS Chem Biol; 2013 Apr; 8(4):679-83. PubMed ID: 23360067
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.
Ho KK; Parnell KM; Yuan Y; Xu Y; Kultgen SG; Hamblin S; Hendrickson TF; Luo B; Foulks JM; McCullar MV; Kanner SB
Bioorg Med Chem Lett; 2013 Jan; 23(2):569-73. PubMed ID: 23232060
[TBL] [Abstract][Full Text] [Related]
10. Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-[2-hydroxyethyl(1-naphthylmethyl)amino]-6-[(2S)-2-methylmorpholin-4-yl]-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance.
Giordanetto F; Wållberg A; Ghosal S; Iliefski T; Cassel J; Yuan ZQ; von Wachenfeldt H; Andersen SM; Inghardt T; Tunek A; Nylander S
Bioorg Med Chem Lett; 2012 Nov; 22(21):6671-6. PubMed ID: 23010262
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening.
Giordanetto F; Kull B; Dellsén A
Bioorg Med Chem Lett; 2011 Jan; 21(2):829-35. PubMed ID: 21169017
[TBL] [Abstract][Full Text] [Related]
12. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways.
Garcia A; Kim S; Bhavaraju K; Schoenwaelder SM; Kunapuli SP
Biochem J; 2010 Jul; 429(2):369-77. PubMed ID: 20441566
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new azaindole-based PI3Kα inhibitors: apoptotic and antiangiogenic effect on cancer cells.
Hong S; Lee S; Kim B; Lee H; Hong SS; Hong S
Bioorg Med Chem Lett; 2010 Dec; 20(24):7212-5. PubMed ID: 21067921
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors.
Cao S; Cao R; Liu X; Luo X; Zhong W
Molecules; 2016 Jul; 21(7):. PubMed ID: 27384552
[TBL] [Abstract][Full Text] [Related]
15. Discovery of piperidinyl aminopyrimidine derivatives as IKK-2 inhibitors.
Kim S; Jung JK; Lee HS; Kim Y; Kim J; Choi K; Baek DJ; Moon B; Oh KS; Lee BH; Shin KJ; Pae AN; Nam G; Roh EJ; Cho YS; Choo H
Bioorg Med Chem Lett; 2011 May; 21(10):3002-6. PubMed ID: 21489792
[TBL] [Abstract][Full Text] [Related]
16. Morpholine derivatives greatly enhance the selectivity of mammalian target of rapamycin (mTOR) inhibitors.
Zask A; Kaplan J; Verheijen JC; Richard DJ; Curran K; Brooijmans N; Bennett EM; Toral-Barza L; Hollander I; Ayral-Kaloustian S; Yu K
J Med Chem; 2009 Dec; 52(24):7942-5. PubMed ID: 19916508
[TBL] [Abstract][Full Text] [Related]
17. Discovery and optimization of indoles and 7-azaindoles as Rho kinase (ROCK) inhibitors (part-I).
Chowdhury S; Sessions EH; Pocas JR; Grant W; Schröter T; Lin L; Ruiz C; Cameron MD; Schürer S; LoGrasso P; Bannister TD; Feng Y
Bioorg Med Chem Lett; 2011 Dec; 21(23):7107-12. PubMed ID: 22004718
[TBL] [Abstract][Full Text] [Related]
18. Aminopyridine carboxamides as c-Jun N-terminal kinase inhibitors: targeting the gatekeeper residue and beyond.
Liu G; Zhao H; Liu B; Xin Z; Liu M; Kosogof C; Szczepankiewicz BG; Wang S; Clampit JE; Gum RJ; Haasch DL; Trevillyan JM; Sham HL
Bioorg Med Chem Lett; 2006 Nov; 16(22):5723-30. PubMed ID: 16971120
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of phosphatidylinositol 3-kinase (PI3K) inhibitory analogues of the sponge meroterpenoid liphagal.
Pereira AR; Strangman WK; Marion F; Feldberg L; Roll D; Mallon R; Hollander I; Andersen RJ
J Med Chem; 2010 Dec; 53(24):8523-33. PubMed ID: 21121631
[TBL] [Abstract][Full Text] [Related]
20. Discovery of triazine-benzimidazoles as selective inhibitors of mTOR.
Peterson EA; Andrews PS; Be X; Boezio AA; Bush TL; Cheng AC; Coats JR; Colletti AE; Copeland KW; DuPont M; Graceffa R; Grubinska B; Harmange JC; Kim JL; Mullady EL; Olivieri P; Schenkel LB; Stanton MK; Teffera Y; Whittington DA; Cai T; La DS
Bioorg Med Chem Lett; 2011 Apr; 21(7):2064-70. PubMed ID: 21376583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
